- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.30 Å
- Oligo State
- hetero-3-3-mer
- Ligands
- 3 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 15 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.2: 4 residues within 4Å:- Chain A: T.190, L.227, N.230, Y.234
3 PLIP interactions:3 interactions with chain A- Hydrogen bonds: A:N.230
- Water bridges: A:N.230, A:N.230
NAG.3: 1 residues within 4Å:- Chain A: N.211
No protein-ligand interaction detected (PLIP)NAG.4: 2 residues within 4Å:- Chain A: N.201, E.202
No protein-ligand interaction detected (PLIP)NAG.5: 5 residues within 4Å:- Chain A: G.237, K.238, R.239, N.241, L.246
2 PLIP interactions:2 interactions with chain A- Hydrogen bonds: A:K.238, A:K.238
NAG.10: 2 residues within 4Å:- Chain B: N.117
- Chain D: T.115
1 PLIP interactions:1 interactions with chain D- Hydrophobic interactions: D:T.115
NAG.15: 4 residues within 4Å:- Chain C: T.190, L.227, N.230, Y.234
3 PLIP interactions:3 interactions with chain C- Hydrogen bonds: C:N.230
- Water bridges: C:N.230, C:N.230
NAG.16: 1 residues within 4Å:- Chain C: N.211
No protein-ligand interaction detected (PLIP)NAG.17: 2 residues within 4Å:- Chain C: N.201, E.202
No protein-ligand interaction detected (PLIP)NAG.18: 5 residues within 4Å:- Chain C: G.237, K.238, R.239, N.241, L.246
2 PLIP interactions:2 interactions with chain C- Hydrogen bonds: C:K.238, C:K.238
NAG.23: 2 residues within 4Å:- Chain D: N.117
- Chain F: T.115
1 PLIP interactions:1 interactions with chain F- Hydrophobic interactions: F:T.115
NAG.28: 4 residues within 4Å:- Chain E: T.190, L.227, N.230, Y.234
3 PLIP interactions:3 interactions with chain E- Hydrogen bonds: E:N.230
- Water bridges: E:N.230, E:N.230
NAG.29: 1 residues within 4Å:- Chain E: N.211
No protein-ligand interaction detected (PLIP)NAG.30: 2 residues within 4Å:- Chain E: N.201, E.202
No protein-ligand interaction detected (PLIP)NAG.31: 5 residues within 4Å:- Chain E: G.237, K.238, R.239, N.241, L.246
2 PLIP interactions:2 interactions with chain E- Hydrogen bonds: E:K.238, E:K.238
NAG.36: 2 residues within 4Å:- Chain B: T.115
- Chain F: N.117
1 PLIP interactions:1 interactions with chain B- Hydrophobic interactions: B:T.115
- 12 x GOL: GLYCEROL(Non-functional Binders)
GOL.6: 5 residues within 4Å:- Chain A: E.93, C.94, L.95, P.96, D.123
2 PLIP interactions:2 interactions with chain A- Hydrogen bonds: A:L.95
- Water bridges: A:A.97
GOL.7: 5 residues within 4Å:- Chain A: G.64, V.65, P.66, D.123, F.124
5 PLIP interactions:1 interactions with chain E, 4 interactions with chain A- Water bridges: E:R.103, A:V.65
- Hydrogen bonds: A:G.64, A:D.123, A:D.123
GOL.11: 6 residues within 4Å:- Chain B: N.62, E.63, T.65, Q.66
- Chain F: W.30
- Ligands: NAG-NAG-BMA-MAN-MAN.1
4 PLIP interactions:4 interactions with chain B- Hydrogen bonds: B:N.62, B:E.63, B:T.65, B:Q.66
GOL.12: 6 residues within 4Å:- Chain A: S.5, D.20, V.21
- Chain B: K.87, D.90
- Chain E: N.34
2 PLIP interactions:1 interactions with chain B, 1 interactions with chain E- Hydrogen bonds: B:K.87, E:N.34
GOL.19: 5 residues within 4Å:- Chain C: E.93, C.94, L.95, P.96, D.123
2 PLIP interactions:2 interactions with chain C- Hydrogen bonds: C:L.95
- Water bridges: C:A.97
GOL.20: 5 residues within 4Å:- Chain C: G.64, V.65, P.66, D.123, F.124
5 PLIP interactions:4 interactions with chain C, 1 interactions with chain A- Hydrogen bonds: C:G.64, C:D.123, C:D.123
- Water bridges: C:V.65, A:R.103
GOL.24: 6 residues within 4Å:- Chain B: W.30
- Chain D: N.62, E.63, T.65, Q.66
- Ligands: NAG-NAG-BMA-MAN-MAN.14
4 PLIP interactions:4 interactions with chain D- Hydrogen bonds: D:N.62, D:E.63, D:T.65, D:Q.66
GOL.25: 6 residues within 4Å:- Chain A: N.34
- Chain C: S.5, D.20, V.21
- Chain D: K.87, D.90
2 PLIP interactions:1 interactions with chain A, 1 interactions with chain D- Hydrogen bonds: A:N.34, D:K.87
GOL.32: 5 residues within 4Å:- Chain E: E.93, C.94, L.95, P.96, D.123
2 PLIP interactions:2 interactions with chain E- Hydrogen bonds: E:L.95
- Water bridges: E:A.97
GOL.33: 5 residues within 4Å:- Chain E: G.64, V.65, P.66, D.123, F.124
5 PLIP interactions:1 interactions with chain C, 4 interactions with chain E- Water bridges: C:R.103, E:V.65
- Hydrogen bonds: E:G.64, E:D.123, E:D.123
GOL.37: 6 residues within 4Å:- Chain D: W.30
- Chain F: N.62, E.63, T.65, Q.66
- Ligands: NAG-NAG-BMA-MAN-MAN.27
4 PLIP interactions:4 interactions with chain F- Hydrogen bonds: F:N.62, F:E.63, F:T.65, F:Q.66
GOL.38: 6 residues within 4Å:- Chain C: N.34
- Chain E: S.5, D.20, V.21
- Chain F: K.87, D.90
2 PLIP interactions:1 interactions with chain C, 1 interactions with chain F- Hydrogen bonds: C:N.34, F:K.87
- 6 x GKZ: 1-[2-[4-[4-(4-chlorophenyl)-3-methyl-1~{H}-pyrazol-5-yl]-3-oxidanyl-phenoxy]ethyl]piperidin-1-ium-4-carboxamide(Non-covalent)
GKZ.8: 9 residues within 4Å:- Chain A: I.11, L.159, P.160, A.162, K.163, K.164
- Chain B: M.47, L.53
- Ligands: GKZ.13
7 PLIP interactions:1 interactions with chain B, 6 interactions with chain A- Halogen bonds: B:L.53
- Hydrophobic interactions: A:I.11, A:L.159, A:P.160
- Water bridges: A:R.37, A:P.160, A:Q.161
GKZ.13: 17 residues within 4Å:- Chain A: T.33, N.34, R.37, V.39, G.40, E.73, A.74, G.75
- Chain B: L.14, Y.16, T.18, T.19, D.21, M.47, L.57
- Chain D: R.86
- Ligands: GKZ.8
21 PLIP interactions:11 interactions with chain B, 8 interactions with chain A, 2 interactions with chain D- Hydrophobic interactions: B:L.14, B:Y.16, B:Y.16, B:Y.16, B:T.18, B:M.47, B:L.57, A:V.39, A:A.74, A:A.74
- Hydrogen bonds: B:Y.16, B:Y.16, A:T.33, A:R.37, D:R.86, D:R.86
- Salt bridges: B:D.21, A:E.73
- pi-Stacking: B:Y.16
- pi-Cation interactions: A:R.37
- Halogen bonds: A:G.40
GKZ.21: 9 residues within 4Å:- Chain C: I.11, L.159, P.160, A.162, K.163, K.164
- Chain D: M.47, L.53
- Ligands: GKZ.26
7 PLIP interactions:1 interactions with chain D, 6 interactions with chain C- Halogen bonds: D:L.53
- Hydrophobic interactions: C:I.11, C:L.159, C:P.160
- Water bridges: C:R.37, C:P.160, C:Q.161
GKZ.26: 17 residues within 4Å:- Chain C: T.33, N.34, R.37, V.39, G.40, E.73, A.74, G.75
- Chain D: L.14, Y.16, T.18, T.19, D.21, M.47, L.57
- Chain F: R.86
- Ligands: GKZ.21
21 PLIP interactions:11 interactions with chain D, 8 interactions with chain C, 2 interactions with chain F- Hydrophobic interactions: D:L.14, D:Y.16, D:Y.16, D:Y.16, D:T.18, D:M.47, D:L.57, C:V.39, C:A.74, C:A.74
- Hydrogen bonds: D:Y.16, D:Y.16, C:T.33, C:R.37, F:R.86, F:R.86
- Salt bridges: D:D.21, C:E.73
- pi-Stacking: D:Y.16
- pi-Cation interactions: C:R.37
- Halogen bonds: C:G.40
GKZ.34: 9 residues within 4Å:- Chain E: I.11, L.159, P.160, A.162, K.163, K.164
- Chain F: M.47, L.53
- Ligands: GKZ.39
7 PLIP interactions:6 interactions with chain E, 1 interactions with chain F- Hydrophobic interactions: E:I.11, E:L.159, E:P.160
- Water bridges: E:R.37, E:P.160, E:Q.161
- Halogen bonds: F:L.53
GKZ.39: 17 residues within 4Å:- Chain B: R.86
- Chain E: T.33, N.34, R.37, V.39, G.40, E.73, A.74, G.75
- Chain F: L.14, Y.16, T.18, T.19, D.21, M.47, L.57
- Ligands: GKZ.34
21 PLIP interactions:8 interactions with chain E, 11 interactions with chain F, 2 interactions with chain B- Hydrophobic interactions: E:V.39, E:A.74, E:A.74, F:L.14, F:Y.16, F:Y.16, F:Y.16, F:T.18, F:M.47, F:L.57
- Hydrogen bonds: E:T.33, E:R.37, F:Y.16, F:Y.16, B:R.86, B:R.86
- Salt bridges: E:E.73, F:D.21
- pi-Cation interactions: E:R.37
- Halogen bonds: E:G.40
- pi-Stacking: F:Y.16
- 3 x DMS: DIMETHYL SULFOXIDE(Non-functional Binders)
DMS.9: 2 residues within 4Å:- Chain A: Y.186, S.188
1 PLIP interactions:1 interactions with chain A- Hydrogen bonds: A:S.188
DMS.22: 2 residues within 4Å:- Chain C: Y.186, S.188
1 PLIP interactions:1 interactions with chain C- Hydrogen bonds: C:S.188
DMS.35: 2 residues within 4Å:- Chain E: Y.186, S.188
1 PLIP interactions:1 interactions with chain E- Hydrogen bonds: E:S.188
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Shaikh, F. et al., Structure-Based in Silico Screening Identifies a Potent Ebolavirus Inhibitor from a Traditional Chinese Medicine Library. J.Med.Chem. (2019)
- Release Date
- 2019-02-27
- Peptides
- Envelope glycoprotein,Envelope glycoprotein,Envelope glycoprotein: ACE
Envelope glycoprotein: BDF - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AC
AE
AB
BD
BF
B
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.30 Å
- Oligo State
- hetero-3-3-mer
- Ligands
- 3 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 15 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 12 x GOL: GLYCEROL(Non-functional Binders)
- 6 x GKZ: 1-[2-[4-[4-(4-chlorophenyl)-3-methyl-1~{H}-pyrazol-5-yl]-3-oxidanyl-phenoxy]ethyl]piperidin-1-ium-4-carboxamide(Non-covalent)
- 3 x DMS: DIMETHYL SULFOXIDE(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Shaikh, F. et al., Structure-Based in Silico Screening Identifies a Potent Ebolavirus Inhibitor from a Traditional Chinese Medicine Library. J.Med.Chem. (2019)
- Release Date
- 2019-02-27
- Peptides
- Envelope glycoprotein,Envelope glycoprotein,Envelope glycoprotein: ACE
Envelope glycoprotein: BDF - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AC
AE
AB
BD
BF
B